Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomaterials legislation

This article was originally published in The Gray Sheet

Executive Summary

The House likely will take up the "Biomaterials Access Assurance Act" (HR 872) under a suspension of the rules on July 27, House staffers say. Passage of the bill, which contains liability protections for biomaterials suppliers whose products are included in medical devices, could revive the issue in the Senate, where a broader product liability compromise containing biomaterials provisions nearly identical to the House bill was defeated July 9 ("The Gray Sheet" July 13, p. 5)
UsernamePublicRestriction

Register

MT010391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel